A citation-based method for searching scientific literature

Junmin Wang, Hongjiao Xiang, Yifei Lu, Tao Wu, Guang Ji. Biomed Pharmacother 2021
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
294
66

Effects of Selonsertib in Patients with Diabetic Kidney Disease.
Glenn M Chertow, Pablo E Pergola, Fang Chen, Brian J Kirby, John S Sundy, Uptal D Patel. J Am Soc Nephrol 2019
39
33

ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice.
Greg H Tesch, Frank Y Ma, Yingjie Han, John T Liles, David G Breckenridge, David J Nikolic-Paterson. Diabetes 2015
57
33

hs-CRP Is Associated With Incident Diabetic Nephropathy: Findings From the Jackson Heart Study.
Satyesh K Sinha, Susanne B Nicholas, Jung Hye Sung, Adolfo Correa, Tripathi B Rajavashisth, Keith C Norris, Jae Eun Lee. Diabetes Care 2019
13
33

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
Jean-Philippe Bertocchio, David G Warnock, Frederic Jaisser. Kidney Int 2011
90
33

Macrophage accumulation in human progressive diabetic nephropathy.
Duy Nguyen, Fu Ping, Wei Mu, Prudence Hill, Robert C Atkins, Steven J Chadban. Nephrology (Carlton) 2006
185
33

Characterization of a coronary vasoconstrictor produced by cultured endothelial cells.
K A Hickey, G Rubanyi, R J Paul, R F Highsmith. Am J Physiol 1985
553
33

Glomerular hyperfiltration and renal disease progression in type 2 diabetes.
Piero Ruggenenti, Esteban L Porrini, Flavio Gaspari, Nicola Motterlini, Antonio Cannata, Fabiola Carrara, Claudia Cella, Silvia Ferrari, Nadia Stucchi, Aneliya Parvanova,[...]. Diabetes Care 2012
191
33

Mechanisms of Regulation of the Chemokine-Receptor Network.
Martin J Stone, Jenni A Hayward, Cheng Huang, Zil E Huma, Julie Sanchez. Int J Mol Sci 2017
124
33

Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Ali F Abdel-Wahab, Ghazi A Bamagous, Randa M Al-Harizy, Naser A ElSawy, Naiyer Shahzad, Ibrahim A Ibrahim, Saeed S Al Ghamdi. Biomed Pharmacother 2018
18
33

Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.
M Saitoh, H Nishitoh, M Fujii, K Takeda, K Tobiume, Y Sawada, M Kawabata, K Miyazono, H Ichijo. EMBO J 1998
33

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink,[...]. N Engl J Med 2013
599
33

Role of the JAK/STAT signaling pathway in diabetic nephropathy.
Mario B Marrero, Amy K Banes-Berceli, David M Stern, Douglas C Eaton. Am J Physiol Renal Physiol 2006
142
33

Avosentan for overt diabetic nephropathy.
Johannes F E Mann, Damian Green, Kenneth Jamerson, Luis M Ruilope, Susan J Kuranoff, Thomas Littke, Giancarlo Viberti. J Am Soc Nephrol 2010
317
33

BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
Sambasiva Rao Kolati, Eshvendar Reddy Kasala, Lakshmi Narendra Bodduluru, Jalandhar Reddy Mahareddy, Shravan Kumar Uppulapu, Ranadeep Gogoi, Chandana C Barua, Mangala Lahkar. Environ Toxicol Pharmacol 2015
49
33

Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
64
33

Origin and evolution of adaptive immunity.
Thomas Boehm, Jeremy B Swann. Annu Rev Anim Biosci 2014
58
33


Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice.
Rita E Mirza, Milie M Fang, Eileen M Weinheimer-Haus, William J Ennis, Timothy J Koh. Diabetes 2014
146
33

Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study.
S Araki, M Haneda, D Koya, T Sugimoto, K Isshiki, M Chin-Kanasaki, T Uzu, A Kashiwagi. Diabetologia 2007
55
33

Drug repurposing in kidney disease.
Usha Panchapakesan, Carol Pollock. Kidney Int 2018
26
33

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.
Lynda A O'Sullivan, Clifford Liongue, Rowena S Lewis, Sarah E M Stephenson, Alister C Ward. Mol Immunol 2007
219
33


Innate immunity.
R Medzhitov, C Janeway. N Engl J Med 2000
33

Endothelin Blockade in Diabetic Kidney Disease.
Lidia Anguiano, Marta Riera, Julio Pascual, María José Soler. J Clin Med 2015
26
33

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.
Maria Vanessa Perez-Gomez, Maria Dolores Sanchez-Niño, Ana Belen Sanz, Catalina Martín-Cleary, Marta Ruiz-Ortega, Jesus Egido, Juan F Navarro-González, Alberto Ortiz, Beatriz Fernandez-Fernandez. J Clin Med 2015
40
33

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
Hiroki Fujita, Tsukasa Morii, Hiromi Fujishima, Takehiro Sato, Tatsunori Shimizu, Mihoko Hosoba, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2014
173
33

Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes.
J Lin, F B Hu, C Mantzoros, G C Curhan. Diabetologia 2010
37
33

Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.
F Y Chow, D J Nikolic-Paterson, E Ozols, R C Atkins, B J Rollin, G H Tesch. Kidney Int 2006
329
33

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits.
Giovanna Leoncini, Elisa Russo, Elisabetta Bussalino, Cecilia Barnini, Francesca Viazzi, Roberto Pontremoli. Int J Mol Sci 2021
3
33

Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.
Qing Qing Wu, Yanxia Wang, Martin Senitko, Colin Meyer, W Christian Wigley, Deborah A Ferguson, Eric Grossman, Jianlin Chen, Xin J Zhou, John Hartono,[...]. Am J Physiol Renal Physiol 2011
128
33

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
Chih-Wei Lin, Nael M Mostafa, Dennis L Andress, John J Brennan, Cheri E Klein, Walid M Awni. Clin Ther 2018
10
33

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.
Jeremy D Gale, Steven Gilbert, Samuel Blumenthal, Tom Elliott, Pablo E Pergola, Kosalaram Goteti, Wim Scheele, Christelle Perros-Huguet. Kidney Int Rep 2018
25
33

Cyclic nucleotide phosphodiesterases: relating structure and function.
S H Francis, I V Turko, J D Corbin. Prog Nucleic Acid Res Mol Biol 2001
447
33


Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
Celine C Berthier, Hongyu Zhang, MaryLee Schin, Anna Henger, Robert G Nelson, Berne Yee, Anissa Boucherot, Matthias A Neusser, Clemens D Cohen, Christin Carter-Su,[...]. Diabetes 2009
215
33


Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
Carla Zoja, Daniela Corna, Valeria Nava, Monica Locatelli, Mauro Abbate, Flavio Gaspari, Fabiola Carrara, Fabio Sangalli, Giuseppe Remuzzi, Ariela Benigni. Am J Physiol Renal Physiol 2013
77
33



The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
Brendan B McCormick, Amy Sydor, Ayub Akbari, Dean Fergusson, Steve Doucette, Greg Knoll. Am J Kidney Dis 2008
80
33

Endothelin and endothelin antagonists in chronic kidney disease.
Donald E Kohan, Matthias Barton. Kidney Int 2014
123
33


Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.
A Festa, R D'Agostino, G Howard, L Mykkänen, R P Tracy, S M Haffner. Kidney Int 2000
277
33


A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.
LuAnn Sabounjian, Philip Graham, Lijun Wu, Virginia Braman, Changfu Cheng, Julie Liu, James Shipley, Joel Neutel, Michael Dao. Clin Pharmacol Drug Dev 2016
11
33

Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Wim Scheele, Susan Diamond, Jeremy Gale, Valerie Clerin, Nihad Tamimi, Vu Le, Rosalind Walley, Fernando Grover-Páez, Christelle Perros-Huguet, Timothy Rolph,[...]. J Am Soc Nephrol 2016
29
33


Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Am J Nephrol 2019
62
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.